EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept

Massimo Imazio iD, Allan L Klein iD, Antonio Brucato iD, Antonio Abbate iD, Michael Arad iD, Paul C Cremer iD, Antonella Insalaco, Martin M LeWinter iD, Basil S Lewis iD, David Lin, Sushil A Luis iD, Stephen J Nicholls und 7 weitere

Journal of the American Heart Association · 19.03.2024 · 13 (6)

DOI: 10.1161/jaha.123.032516 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 19.03.2024. Verfasst von Massimo Imazio und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (DMED), University of Udine and Cardiothoracic Department University Hospital Santa Maria della Misericordia, ASUFC Udine Ital…. Hauptthemen laut MEDLINE: Interleukin-1alpha, Pericarditis. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Rilonacept, a once‐weekly interleukin‐1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin‐1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Symptomatology and Outcomes Study). The RHAPSODY long‐term extension further explored recurrent pericarditis natural history and treatment duration decision‐making during 24 additional months of open‐label rilonacept treatment. Methods and Results Seventy‐four patients commenced the long‐term extension, with a median (maximum) total rilonacept duration of 22 (35) months. Individually, 18 months after the most proximal pericarditis recurrence, investigators decided to continue rilonacept on study, suspend rilonacept for off‐treatment observation (rescue allowed), or discontinue the study. The annualized incidence of pericarditis recurrence on rilonacept up to the 18‐month decision milestone was 0.04 events/patient‐year versus 4.4 events/patient‐year prestudy while on oral therapies. At the 18‐month decision milestone, 64% (33/52) continued rilonacept, 15% (8/52) suspended rilonacept for observation, and 21% (11/52) discontinued the study. Among the 33 patients (1/33; 3.0%) continuing rilonacept (median time to recurrence could not be estimated due to too few events), a single recurrence occurred 4 weeks after a treatment interruption. Among patients suspending rilonacept, 75% (6/8) experienced recurrence (median time to recurrence, 11.8 weeks [95% CI, 3.7 weeks to not estimable]). There was a 98% reduction in risk of pericarditis recurrence among patients continuing rilonacept treatment after the 18‐month decision milestone versus those suspending treatment for observation (hazard ratio, 0.02; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1alphaPericarditisHumansRecombinant Fusion ProteinsRecurrenceRisk Reduction BehaviorTreatment Outcome

Stichwörter der Autor:innen

autoinflammatory diseaseinterleukin‐1recurrent pericarditisrilonacept

Substanzen

Interleukin-1alphaRecombinant Fusion Proteinsrilonacept

Autor:innen und Institutionen

  • Department of Medicine (DMED), University of Udine and Cardiothoracic Department University Hospital Santa Maria della Misericordia, ASUFC Udine Italy.
  • Cleveland Clinic Cleveland OH USA.
  • University of Milano, Fatebenefratelli Hospital Milan Italy.
  • Berne Cardiovascular Research Center, School of Medicine University of Virginia Charlottesville VA USA.
  • Leviev Heart Center, Ramat Gan Tel Aviv University School of Medicine Ramat Gan Israel.
  • Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center] Rome Italy.

ORCID-Profile: Massimo Imazio, Allan L Klein, Antonio Brucato, Antonio Abbate, Michael Arad, Paul C Cremer, Martin M LeWinter, Basil S Lewis, Sushil A Luis, Yishay Wasserstrum, JoAnn Clair, John F Paolini

Zitieren

APA

Imazio, M., Klein, A. L., Brucato, A., Abbate, A., Arad, M., Cremer, P. C., Insalaco, A., LeWinter, M. M., Lewis, B. S., Lin, D., Luis, S. A., Nicholls, S. J., Sutej, P., Wasserstrum, Y., Clair, J., Agarwal, I., Wang, S., Paolini, J. F., & RHAPSODY Investigators (2024). Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept. Journal of the American Heart Association, 13(6). https://doi.org/10.1161/jaha.123.032516

Vancouver

Imazio M, Klein AL, Brucato A, Abbate A, Arad M, Cremer PC, et al. Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept. Journal of the American Heart Association. 2024;13(6). doi:10.1161/jaha.123.032516

BibTeX
@article{Imazio2024,
  author = {Imazio, Massimo and Klein, Allan L and Brucato, Antonio and Abbate, Antonio and Arad, Michael and Cremer, Paul C and Insalaco, Antonella and LeWinter, Martin M and Lewis, Basil S and Lin, David and Luis, Sushil A and Nicholls, Stephen J and Sutej, Paul and Wasserstrum, Yishay and Clair, JoAnn and Agarwal, Indra and Wang, Sheldon and Paolini, John F and RHAPSODY Investigators, RHAPSODY Investigators},
  title = {Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {6},
  doi = {10.1161/jaha.123.032516}
}
Kostenlos starten →